Current location:Home > Metabolic Pipeline > Biologics

Biologics

Peptide based therapies for metabolic diseases, including the next-generation insulin analogs and ultra long-acting GLP-1 receptor agonists.

GLP-1 RA

Bofanglutide (GZR18 Injection)

A biweekly GLP-1 RA indicated for the treatment of obesity/overweight and associated comorbidities, T2DM, and other metabolic diseases.

Potentially the first approved biweekly GLP-1 RA worldwide
Business development in LATAM, India, South Korea

ADA 2026 Highlights

Renal Impairment

PK and Safety of Bofanglutide

View Poster >

Drug-Drug Interaction

PK Interaction Between Bofanglutide and Metformin

View Poster >

Clinical Progress

Pre-clinical Results

Phase 1 Clinical Results

Phase 2 Clinical Results (T2DM)

Phase 2 Clinical Results (Overweight/obesity)

Phase 3 Clinical Design

Molecular Design

Molecular Design

Insulin

Insulin Ludefen (GZR4 Injection)

An investigational ultra-long-acting once-weekly basal insulin analog.

Potentially the world's first approved China-developed once-weekly basal insulin

ADA 2026 Highlight

Renal Impairment

Effects of Mild or Moderate Renal Impairment on PK and Safety

View Poster >

Clinical Progress

Pre-clinical Results

Phase 1 Clinical Results

Phase 1b Clinical Results

Phase 2 Clinical Results

Phase 3 Clinical Design

Molecular Design

Molecular Design

Basal insulin and GLP-1 RA

GZR102 Injection

A once-weekly fixed-ratio combination of basal insulin and GLP-1 RA intended for subcutaneous treatment of type 2 diabetes.
- Potentially the first approved China-developed once-weekly fixed-ratio combination of basal insulin and GLP-1 RA.
ADA 2026 Highlight

Pre-clinical Results

PK/PD

View Poster >
Insulin

GZR33/GZR101 Injection

GZR33: A novel once-daily long-acting basal insulin analog for the treatment of diabetes mellitus, designed to provide stable and sustained fasting glucose control.
GZR101: A novel premixed insulin for the treatment of diabetes mellitus, comprising a novel long-acting basal insulin analog, insulin GZR33 and a marketed insulin aspart (Rapilin®).

Pre-clinical Results
Insulin Biosimilars

Third-generation Insulin

Ondibta® (Insulin Glargine), Dazparda® (Insulin Aspart) and Bysumlog®(Insulin Lispro) European Marketing Authorization Granted.

• Bioequivalence of Gan & Lee Glargine U300 vs Toujeo® • Efficacy and Safety of Rapilin versus NovoRapid Plus Metformin • Gan & Lee Glargine versus Lantus® in Type 1 Diabetes: A 26-Week Immunogenicity, Efficacy, and Safety Study • Gan & Lee Glargine versus Lantus® in Type 2 Diabetes: A 26-Week Immunogenicity, Efficacy, and Safety Study • PK/PD bioequivalence of Gan & Lee insulin analogues aspart (rapilin®), lispro (prandilin®) and glargine (basalin®) with EU- und US-sourced reference insulins